Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.
Guillaume DecarriereThomas BarnetcheBernard CombeCécile Gaujoux-VialaCédric LukasJacques MorelClaire DaienPublished in: Arthritis care & research (2021)
The different csDMARDs seem safe and efficient to combine with advanced therapies in RA patients. Although MTX seems slightly superior to other csDMARDs in combination with TNFi, leflunomide might be superior to MTX in combination with rituximab.
Keyphrases
- rheumatoid arthritis
- systematic review
- end stage renal disease
- disease activity
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- interstitial lung disease
- ankylosing spondylitis
- meta analyses
- rheumatoid arthritis patients
- patient reported outcomes
- systemic lupus erythematosus
- randomized controlled trial
- idiopathic pulmonary fibrosis